NSPR Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -503.69% compared to InspireMD, Inc.'s net margin of -12425.36%. InspireMD, Inc.'s return on equity of -121.49% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

InspireMD, Inc. has a consensus price target of $4.50, signalling upside risk potential of 139.36%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 412.82%. Given that Perspective Therapeutics, Inc. has higher upside potential than InspireMD, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than InspireMD, Inc..

InspireMD, Inc. has a beta of 0.696, which suggesting that the stock is 30.446% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

InspireMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InspireMD, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

InspireMD, Inc. quarterly revenues are $2.5M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. InspireMD, Inc.'s net income of -$12.7M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, InspireMD, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD, Inc. is 13.49x versus 162.73x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of -503.69% compared to InspireMD, Inc.'s net margin of 28.31%. InspireMD, Inc.'s return on equity of -121.49% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

InspireMD, Inc. has a consensus price target of $4.50, signalling upside risk potential of 139.36%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $596.36 which suggests that it could grow by 3.65%. Given that InspireMD, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe InspireMD, Inc. is more attractive than Intuitive Surgical, Inc..

InspireMD, Inc. has a beta of 0.696, which suggesting that the stock is 30.446% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.

InspireMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InspireMD, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

InspireMD, Inc. quarterly revenues are $2.5M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. InspireMD, Inc.'s net income of -$12.7M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, InspireMD, Inc.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 76.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD, Inc. is 13.49x versus 21.76x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

908 Devices, Inc. has a net margin of -503.69% compared to InspireMD, Inc.'s net margin of -106.46%. InspireMD, Inc.'s return on equity of -121.49% beat 908 Devices, Inc.'s return on equity of -41.37%.

InspireMD, Inc. has a consensus price target of $4.50, signalling upside risk potential of 139.36%. On the other hand 908 Devices, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 52.21%. Given that InspireMD, Inc. has higher upside potential than 908 Devices, Inc., analysts believe InspireMD, Inc. is more attractive than 908 Devices, Inc..

InspireMD, Inc. has a beta of 0.696, which suggesting that the stock is 30.446% less volatile than S&P 500. In comparison 908 Devices, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

InspireMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 908 Devices, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InspireMD, Inc. pays -- of its earnings as a dividend. 908 Devices, Inc. pays out -- of its earnings as a dividend.

InspireMD, Inc. quarterly revenues are $2.5M, which are smaller than 908 Devices, Inc. quarterly revenues of $14M. InspireMD, Inc.'s net income of -$12.7M is higher than 908 Devices, Inc.'s net income of -$14.9M. Notably, InspireMD, Inc.'s price-to-earnings ratio is -- while 908 Devices, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD, Inc. is 13.49x versus 4.05x for 908 Devices, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -503.69% compared to InspireMD, Inc.'s net margin of 3.93%. InspireMD, Inc.'s return on equity of -121.49% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

InspireMD, Inc. has a consensus price target of $4.50, signalling upside risk potential of 139.36%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Xtant Medical Holdings, Inc. has higher upside potential than InspireMD, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than InspireMD, Inc..

InspireMD, Inc. has a beta of 0.696, which suggesting that the stock is 30.446% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

InspireMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InspireMD, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

InspireMD, Inc. quarterly revenues are $2.5M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. InspireMD, Inc.'s net income of -$12.7M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, InspireMD, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD, Inc. is 13.49x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.